Navigation Links
Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
Date:12/3/2010

MYSTIC, Conn. and DUBLIN, Dec. 3, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 3:00pm PST. The conference will be held at the Nikko Hotel in San Francisco.

A live audio webcast of the presentation will be available at the following URL:  

http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3331020

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate).On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides(>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information, including a summary of MARINE trial top-line results, please visit www.amarincorp.com.Investor Contact Information: John F. Thero President In U.S.: +1 (860) 572-4979 investor.relations@amarincorp.comLee M. Stern The Trout Group In U.S.: +1 (646) 378-2922 lstern@troutgroup.comMedia Contact Information: David Schull or Martina Schwarzkopf, Ph.D.Russo Partners In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office) +1 (347) 591-8785 (mobile) david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.comMark Swallow or David Dible CitigateDeweRogersonIn U.K.: +44 (0)207 638 9571 mark.swallow@citigatedr.co.uk
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
2. Amarin to Present at UBS Life Sciences Conference
3. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
4. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
5. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
6. VIVUS to Present at Two Upcoming Investor Conferences
7. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
8. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
9. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
10. Masimo to Present at Piper Jaffray 22nd Annual Healthcare Conference
11. Beckman Coulter to Present at the Piper Jaffray 22nd Annual Unplugged Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):